In tumours where the MCL-1 level is low and MCL-1 is absent or inactivated, ABT-737 has a significant effect as monotherapy, but ABT-737 monotherapy is not effective in tumours with high MCL-1 expression. The gene discussed is MCL1; the disease is neoplasm.